Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $200.00 short call and a strike $220.00 long call offers a potential 10.44% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $200.00 by expiration. The full premium credit of $1.89 would be kept by the premium seller. The risk of $18.11 would be incurred if the stock rose above the $220.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 58.07 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
3 “Strong Buy” Stocks for the Week
Mon, 13 Aug 2018 19:04:40 +0000
Stocks entered the weekend on a sour note. Turkey currency woes were all the excuse needed to end the multi-day rally that had carried the S&P 500 within a whisker of all-time highs. But one day does not a downtrend make. My weekend scanning revealed many “strong buys” that deserve a top spots on your list of stocks to buy.
Amgen Inc (NASDAQ:AMGN): What You Have To Know Before Buying For The Upcoming Dividend
Mon, 13 Aug 2018 16:37:29 +0000
Attention dividend hunters! Amgen Inc (NASDAQ:AMGN) will be distributing its dividend of US$1.32 per share on the 07 September 2018, and will start trading ex-dividend in 2 days time onRead More…
What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
Mon, 13 Aug 2018 11:30:46 +0000
Alnylam Pharmaceuticals’ (ALNY) investigational RNAi therapeutic drug lumasiran is being developed for the treatment of primary hyperoxaluria type 1 (or PH1). Alnylam expects to initiate a Phase 3 trial of the drug in 2018, with its results expected in late 2019.
4 Biotech Stocks That May Fall By as Much as 13%
Fri, 10 Aug 2018 18:00:00 +0000
Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.
Biotech ETFs in Focus on String of Q2 Earnings Beat
Fri, 10 Aug 2018 17:56:05 +0000
Biotech ETFs draw attention post impressive Q2 results.
Also on Market Tamer…
Follow Us on Facebook